Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
80 hedge funds and large institutions have $219M invested in Avadel Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 16 reducing their positions, and 8 closing their positions.
309% more call options, than puts
Call options by funds: $6.67M | Put options by funds: $1.63M
63% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 16
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 77 → 80 (+3)
0.11% less ownership
Funds ownership: 55.65% → 55.55% (-0.11%)
26% less capital invested
Capital invested by funds: $294M → $219M (-$75.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$3.89M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$2.43M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$1.85M |
| 4 |
TLP
Tri Locum Partners
New York
|
+$1.22M |
| 5 |
Morgan Stanley
New York
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.24M |
| 2 |
BlackRock
New York
|
-$3.85M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$2.48M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.06M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$902K |
AVDL Hedge Fund Activity: Q2 2021 in Review
80 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2021, worth a combined $219M — down 26% from $294M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AVDL positions and 8 closed out — a net gain of 3 holders — while 26 added to existing stakes and 16 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $3.89M. The largest seller was Acuta Capital Partners, cutting an estimated $4.24M.
- 80 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2021, up from 77 in Q1 2021.
- Funds reported $219M of Avadel Pharmaceuticals stock for Q2 2021, down 26% quarter-over-quarter.
- 11 funds opened new Avadel Pharmaceuticals positions in Q2 2021 and 8 closed out, a net change of +3 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2021 was Janus Henderson Group, an estimated $3.89M added.
- The largest Avadel Pharmaceuticals seller in Q2 2021 was Acuta Capital Partners, an estimated $4.24M sold.
Based on aggregated 13F filings for Q2 2021.